Pfizer Report Demonstrates Value of Conducting Virtual Studies of Drug-Drug Interactions
News Jun 12, 2008
A new report to appear in the British Journal of Clinical Pharmacology shows how pharmaceutical companies can use modelling and simulation to predict clinically significant drug-drug interactions before undertaking human studies.
Scientists at Pfizer Global Research and Development (Sandwich, Kent) have used the Simcyp Simulator to predict the extent of drug-drug interactions for maraviroc, which is used in combination with other medications in the treatment of HIV.
The research group used the Simcyp Simulator, together with in vitro data, to predict in vivo outcomes. The results of this ‘virtual’ study were then compared with observed clinical data.
The simulations were found to be in good agreement with the clinical results, which led to the conclusion that validated models of drug-drug interactions within Simcyp allow for the prediction of other metabolic drug-drug interactions without the need for a clinical study.
The report stated: “Simcyp has successfully simulated the extent of clinical interactions with CYP3A4 inhibitors, further validating this software as a good predictor of CYP-based drug-drug interactions.”
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
'Body-on-a-Chip' Could Advance Drug EvaluationNews
MIT engineers have developed new technology that could be used to evaluate new drugs and detect possible side effects before the drugs are tested in humans. Using a microfluidic platform that connects engineered tissues from up to 10 organs, the researchers can accurately replicate human organ interactions for weeks at a time.READ MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.